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Results: A total of 7 RCTs were identiﬁed (2,867 patients). IPD 
analyses are still pending for one trial. The pooled estimate for overall 
survival showed an improvement in favor of docetaxel whatever the 
source data used:
Trial
No. of 
pts
Design
Hazard ratio [95% CI]
Published 
data
Study report 
data
IPD
Fossella F et al. J 
Clin Oncol 2003
1218 
DC vs VC 0.85 [0.70.1.01] 0.85 [0.72;0.99] 0.89 [0.76;1.04]
DCb vs VC 0.95 [0.80;1.14] 0.95 [0.81;1.12] 1.02 [0.88;1.20]
Douillard JY et al. 
Am Oncol 2005
233 DC vs VC 0.89 [0.68;1.16] 0.89 [0.66:1.19] 0.87 [0.66;1.13]
Kubota K et al. J 
Clin Oncol 2004
311 DC vs VdC 0.73 [0.57;0.94] 0.75 [0.58;0.97] 0.71 [0.56.0.91]
Georgoulias V et al. 
J Clin Oncol 2005
413 DG vs VC 1.00 [0.80;1.26] 1.00 [0.80;1.26] 1.02 [0.81;1.27]
Pujol JL et al. Ann 
Oncol 2005
311 DG vs VC 0.90 [0.70;1.16] 0.90 [0.70;1.16]  pending
Kudoh S et al. J Clin 
Oncol 2006
180 D vs VC 0.78 [0.56;1.08] 0.78 [0.56;1.08] 0.78 [0.56;1.08]
Monnier A et al. 
Proc ASCO 2003
201 D vs V  NA (abstract) 0.95 [0.70;1.30] 0.96 [0.70;1.31]
Overall HR 0.88 [0.81;0.96] 0.89 [0.82;0.96] 0.90 [0.82;0.98]
D: docetaxel, C: cisplatin, Cb: carboplatin, G: gemcitabine, V: vinorelbine, Vd: vindesine
Conclusions: For this meta-analysis of survival, IPD conﬁrmed the 
results found with either study report data or published data. The meta-
analysis is currently on-going for other less objective endpoints such 
as tumour response and progression-free survival. Pending data will be 
available and presented at the meeting.
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Background: In the BR.21 phase III placebo-controlled study 
(Shepherd et al. NEJM 2005;353:123-132), erlotinib (Tarceva®) was 
well tolerated and signiﬁcantly improved survival, delayed symptom 
progression and improved quality of life in patients with relapsed 
advanced NSCLC. The multicentre, open-label TRUST study was initi-
ated to provide erlotinib access for patients with stage III/IV advanced 
NSCLC.
Methods: Eligible patients had failed prior chemotherapy, or were 
unsuitable for chemotherapy. Erlotinib was administered orally 150mg/
day until disease progression or unacceptable toxicity. The NCI-CTC 
v3.0 was used to grade toxicities, including: incidence and grade of 
erlotinib-related rash; serious adverse events (SAEs) and treatment-re-
lated SAEs; and adverse events (AEs) leading to treatment withdrawal. 
Other treatment-related AEs were reported if they were not included on 
a list of 15 pre-speciﬁed AEs in the study protocol (rash; pruritis; dry 
skin; diarrhoea; nausea; vomiting; stomatitis; abdominal pain; fatigue; 
dyspnoea; cough; anorexia; infection; conjunctivitis; and keratocon-
junctivitis sicca). Dose reductions (50mg increments) were allowed as 
required.
Results: 5,015 patients from 51 countries were included in the analysis 
at the data cut-off (20/11/06). Median age was 63 years (range 19–95). 
Patient characteristics: male 62%, female 38%; stage IIIB 22%, stage 
IV 78%; ECOG PS 0 21%, PS 1 53%, PS 2 20%, PS 3 6%; Caucasian 
76%, Oriental 19%, other 5%; non-smoker 28%, ever-smoker 71% 
(no data 1%); adenocarcinoma 53%, squamous-cell carcinoma 25%, 
other 21% (no data <1%); erlotinib 1st line 14%, 2nd line 48%, 3rd 
line 37%, other 1%. Data on the occurrence of rash were available for 
4,965 patients, of whom 70% experienced rash, which was mainly 
mild or moderate (among those with rash, 84% of cases were grade 
1/2 and 16% were grade 3/4). AE safety data were available for 4,423 
patients, of whom, 55% experienced at least one AE. Erlotinib-related 
SAEs were experienced by 5% of patients, the most common of these 
being gastrointestinal (GI) disorders (2% all grades, 1% ≥ grade 3). 
Lung-related SAEs occurred in <1% of patients. 10% of patients had 
at least one treatment-related AE that was not pre-speciﬁed (3% had at 
least one grade 3/4 event), but no single such event occurred in more 
than 1% of patients. Treatment discontinuation due to erlotinib-related 
AEs occurred in 6% of patients, mainly due to GI disorders (2% all 
grades, 1% ≥ grade 3) and skin disorders (2% all grades, 1% ≥ grade 
3). Lung-related AEs led to erlotinib withdrawal in <1% of patients. 
Among 4,405 patients with available data, 577 patients (13%) required 
dose reductions due to erlotinib-related events, most commonly related 
to rash (n=416) or diarrhoea (n=72). Safety results for the subgroup of 
patients who received erlotinib second-line were similar to the overall 
results. Efﬁcacy data will be presented.
Conclusions: The safety data obtained in the TRUST study of erlotinib 
in advanced NSCLC conﬁrm in a wider clinical setting the favourable 
safety proﬁle of erlotinib observed in previous clinical trials. Erlotinib 
was generally well tolerated, thus enabling the majority of patients to 
receive the full therapeutic dose.
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Background: Cetuximab (C225) is a chimerized monoclonal antibody 
that targets the epidermal growth factor receptor (EGFR). NSCLC 
commonly expresses the EGFR, which is associated with aggressive 
tumor behavior and poor clinical outcome. Preclinical model systems 
